QMS Medi and HCAH Merge Pharma Services to Create India's Largest PSP Platform
QMS Medical Allied Services and HCAH are merging their pharma services businesses into QMS's subsidiary, Saarathi Healthcare. The combined entity will be India's largest patient support platform, managing over 160 PSPs and impacting over 1.2 million patients. This strategic merger aims to enhance scale and patient care.
This is a significant strategic move that combines two major players in the patient support program space, creating a market leader and positioning the company for substantial growth in a rapidly expanding sector.
The merger is expected to create India's largest patient support platform, leading to greater scale, reach, and value creation for shareholders. The growth potential of the Indian patient support services market further supports a positive outlook.
QMS Medical Allied Services Limited (QMSMEDI) and Health Care At Home India Pvt Ltd (HCAH) have announced a strategic merger of their pharmaceutical services businesses. The combined entity, to be integrated into Saarathi Healthcare, a wholly-owned subsidiary of QMS, will form India's largest patient support program (PSP) platform.
This strategic move aims to leverage complementary capabilities in patient screening, enrolment, therapy initiation, adherence, patient assistance, and disease management. The merged operation will manage over 160 Patient Support Programs, impacting more than 1.2 million patients, with a team of over 2,000 professionals across 35 cities.
Mahesh Makhija, Founder, Chairman & Managing Director of QMS, stated that the combination will create greater scale, reach, and execution capability for pharmaceutical companies, ultimately enhancing value for QMS shareholders. Aditya Burman, Non-Executive Director of HCAH, highlighted the increasing importance of patient support in chronic disease management and how the combined entity will offer a comprehensive continuum of care.
The global patient support services market is valued at approximately $70 billion (₹5,80,000 crore), with the Indian market projected to grow at a CAGR of 15-20% to reach about $1 billion (₹8,300 crore) by 2030. This growth is attributed to stricter regulations, industry formalization, rising chronic diseases, digital adoption, and a focus on patient monitoring.
What to do with a filing like this
QMS Medical Allied Services Limited filed this with the NSE as a statutory disclosure, categorised under merger. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by QMS Medical Allied Services Limited. Read the original for the full detail.